



January 14, 2022

Announcement: site-of-care driven copay assistance for RYPLAZIM® [plasminogen, human-tvmh]

Dear Provider,

Starting in January, providers can assist patients with their RYPLAZIM copays. Eligible patients can receive up to \$20,000 per year to cover their out-of-pocket expenses. This program is administered by Medmonk, Inc., an initiative that provides copay assistance based on predetermined eligibility guidelines.

For patient covered under **pharmacy benefits**, providers must bill the claim to Medmonk as a secondary payer for instant adjudication at **BIN: 016664 PCN: MEDMONK Cardholder ID: MEDMONK**

For patients covered under **medical benefits**, providers must register at <http://ryplazim.medmonk.com> for instant adjudication.

Eligibility Guidelines

- Patients must be commercially insured. **Not valid** for prescriptions eligible for reimbursement by any federal or state healthcare program, such as Medicare, Medicare Advantage plans, Medicaid, PCIP, Champus, Tricare, Veterans Administration (VA), or any other state or federal program.
- Patients must express financial need.
- Assistance available for the treatment of Plasminogen Deficiency type 1.

This program is subject to discontinuation or change by Kedrion Biopharma Inc. at any time, for any reason, and with or without prior notice.

For more information visit <http://ryplazim.medmonk.com>

Sincerely,

Kedrion Biopharma, Inc.